Skip to main content

Table 1 A summary of the drugs used in this study and their inhibitory spectrum against the cellular kinome

From: Short-term culture of tumour slices reveals the heterogeneous sensitivity of human head and neck squamous cell carcinoma to targeted therapies

Name Concentration used Main kinase target Reference
Cetuximab 30 μM EGFR (Epidermal Growth Factor Receptor) [7]
Erlotinib 1 μM EGFR [15]
Afatinib 10 μM EGFR / ErbB2/ ErbB4 [15]
Sorafenib 10 μM B-RAF, C-RAF, PDGFR-A, PDGFR-B (Platelet-Derived Growth Factor Receptor) [15]
VEGFR-2 (Vascular Endothelial Growth Factor-2)
Masitinib 10 μM KIT, PDGFR-A, PDGFR-B [15]
Tivantinib 10 μM HGFR (Hepatocyte Growth Factor Receptor) [16]
Ponatinib 1 μM FGFR1-4 (Fibroblast-Growth Factor Receptor), PDGFR-A, VEGFR-2 [17]
Rapamycin 1 μM mTOR (mammalian Target Of Rapamycin) [18]